ACC: New Stent May Help Treat Bifurcation Lesions
New sideKick stent delivery system may reduce risk of side-branch loss, subsequent heart attack
TUESDAY, March 27 (HealthDay News) -- The first human trial of the new sideKick stent delivery system shows that it may enhance treatment of bifurcation lesions by allowing for stent deployment in the main coronary branch while protecting the side branch, according to research presented this week at the American College of Cardiology's meeting in New Orleans.
David Meerkin, M.D., of the Shaare Zedek Medical Center in Jerusalem, Israel, and colleagues used the sideKick system to treat 17 patients with 20 bifurcation lesions.
The researchers found that the procedure was successful in treating 16 cases, or 80 percent. Postdilation was necessary in only six cases, and side-branch angioplasty was necessary in four cases after stent deployment. They observed no major adverse cardiac events in-hospital, but identified one case of subacute thrombosis resulting in a Q wave myocardial infarction at the 30-day follow-up.
"This system may offer the interventional cardiologist a simpler procedure with less risk of side-branch loss and subsequent heart attack," Meerkin said in a statement.